

## EXTENDED EXPERIMENTAL PROCEDURES

### Fly Stocks

Fly stocks used are: *y w; UAS-foxo-TM* (constitutive active); *y w; UAS-foxo transgene #1 #a* (Hwangbo et al., 2004); *y w; UAS-foxo transgene #2*, and *y w; foxo<sup>21</sup>* and *y w; foxo<sup>25</sup>* (Junger et al., 2003; Zheng et al., 2007); *y w, UAS-foxo transgene #b* (Puig et al., 2003); *y w, UAS-4E-BP CA* ((Miron et al., 2001); Bloomington #24854; recombined on *y w*); *4E-BP/Thor-lacZ* (Bloomington #9558); *y w; UAS-Pten* ((Huang et al., 1999); recombined on *y w*); *y w; Mhc-GFP* (*WeeP26*; Clyne et al., 2003); *UAS-Lamp1-GFP* (Pulipparacharuvi et al., 2005); *y w; UAS-GFP-Atg5* (Bloomington #8731; (Rusten et al., 2004)); *UAS-HD-Q72-GFP* and *UAS-HD-Q103-GFP* (gift of Sheng Zhang, University of Texas); *y w; Dmef2-Gal4* (Ranganayakulu et al., 1996); *w; UAS-srcGFP* (Bloomington #5432); *S106GS-Gal4* (Giannakou et al., 2004); and *w; Mhc-Gal4* (Schuster et al., 1996). RNAi stocks to knock-down *Atg7* (JF02787) and *white* (JF01786) mRNA levels were provided by the DRSC/TRiP at Harvard Medical School. *UAS-Hsp70* transgenic flies were generated by cloning the *Hsp70* coding sequence in the pUAST vector followed by injection into *w<sup>1118</sup>* embryos.

### Antibodies and Immunostaining Procedures

Antibodies used are: anti- $\beta$ -galactosidase (Promega, 1:200), anti-GFP (Abcam, 1:200), anti-polyubiquitin (FK2; Assay Designs, 1:200), anti-Hsp70 (1:200; gift of Susan Lindquist), anti-Ref(2)P (1:1000; gift of Ioannis Nezis (Nezis et al., 2008)), anti-Tropomyosin (Babraham Institute, 1:100), and/or anti-Dilp2 and anti-Dilp5 (Geminard et al., 2009) antibodies.

After incubation with primary antibodies over night, the samples were washed, and incubated with Alexa488 or Alexa635-conjugated phalloidin (1:100), to visualize F-actin, and with Alexa-conjugated secondary antibodies (Molecular Probes, 1:200). Nuclei were visualized by DAPI staining (1  $\mu$ g/ml). Samples were processed with a Leica SP2 laser scanning confocal microscope.

### Detailed Behavioral and Metabolic Assays

CAFÉ feeding behavior assays were done as previously (Ja et al., 2007; Xu et al., 2008). In brief, twelve hours before the assay, 7 flies were transferred from normal food to 1.5% agar vials and fed 5% sucrose solution maintained in 5  $\mu$ l calibrated glass micropipettes (VWR, #53432-706). At the start of the assay, the old micropipette was replaced with a new one. The amount of liquid food consumed was recorded every 2 hr and corrected on the basis of the evaporation observed in a vial without flies.

Feeding assays on blue colored food were done by providing food containing 5% sucrose, 1% agar, and 0.5% brilliant blue for 24 hr. Blue dye ingestion was quantified by measuring the absorbance at 625 nm of batches of 4 flies, as done previously (Xu et al., 2008). For measurement of body weight, groups of 7 flies were weighted on a precision balance and the average body weight calculated.

The quantification of the glucose concentration in the hemolymph was done according to Geminard et al., (2009). In brief, at least 15 flies were decapitated, placed in a perforated 0.5 ml tube, centrifuged for 6 min at 1500 g, and the hemolymph collected in an underlying 1.5 ml tube at 4°C. The hemolymph was diluted 1:10 in distilled water and the glucose concentration was determined with the Glucose Hexokinase Assay kit (Sigma #GAHK-20) after trehalose conversion into glucose with porcine trehalase (Sigma #T8778) and incubation at 37°C overnight. All experiments were done with male flies.

### Cell Culture and Luciferase Assays

For transcriptional assays, S2R+ cells were transfected with the following plasmids: pMT-foxo (Puig et al., 2003), actin-firefly Luciferase, and either wild-type or mutant versions of *Renilla* Luciferase reporters based on the promoters of Hsp70, Hsp40, and Hsp90. *Renilla* Luciferase reporters were constructed and mutagenized via a standard PCR-based approach. Luciferase activity refers to the ratio of *Renilla* to firefly Luciferase luminescence.

### List of qPCR Primers

Alpha-Tubulin84B (CG1913):

5'-GCTGTTCCACCCCGAGCAGCTGATC-3' and 5'-GGCGAACTCCAGCTTGGACTTCTTGC-3'

Thor/4E-BP (CG8846):

5'-TCCTGGAGGCACCAAATTATC-3' and 5'-GGAGCCACGGAGATTCTTCA-3'

Hsp70Bbb (CG5834):

5'-GGAGACACACACTTGGGCGGCGAG-3' and 5'-TCTCGATGGTGGCCTCCGTGCTAG-3'

Hip (CG2947):

5'-TCCCAGGTGTGAGCCGCCATTCAGGAC-3' and 5'-CAAACCGTCATCGACGAAGTCGGCGGAG-3'

Hop (CG2720):

5'-AAGGCCTTGAAGCGTACAACGAGGGTC-3' and 5'-TCCTCTACCCGAGGTTTACGCGGGCTTTG-3'

Hsp40 (*DnaJ-like-1*, CG10578):

5'-CTACAAGATTCTGGGCTCGAGCGC-3' and 5'-CGTAATTGTGAAGATGTCGCGCTTC-3'

Hsp90 (*Hsp83*, CG1242):

5'-AGAAGCAGAGACCTTTGCATTCCAG-3' and 5'-AGCTTGATGTACAGCTCCTTGCCAG-3'

CHIP (CG5203):

5'-TTGCTACTCAAAGGCCATCATAAAG-3' and 5'-TATGCCCGTTGAAGGTGCTTTATAG-3'  
*Chap1* (CG14224):  
 5'-ACGGTCAAGTTGACGAAGATTCTGG-3' and 5'-AAAGGGCGTTGGCGCACGTGAC-3'  
*Hsc70.1* (CG8937):  
 5'-GAATCCCAACAACACGATCTTTGATG-3' and 5'-AGGTAGGCCTCCGCGGTCTCTC-3'  
*Atg1* (CG10967):  
 5'-CGTCTACAAAGGACGTCATCGCAAGAAAC-3' and 5'-CGCCAAGTCGCCGCCATTGCAATACTC-3'  
*Atg5* (CG1643):  
 5'-CCTGCGAATCTATACAGACGATGAC-3' and 5'-AGCTCAGATGCTCGGACATCCATTG-3'  
*Atg6* (CG5429):  
 5'-TGCACGCAATGGCGGAGTTATCTTTGC-3' and 5'-CAGCTCCGCTTTCAGCTTAAAAGCAGC-3'  
*Atg7* (CG5489):  
 5'-TGCCTTTCTGCTTCAGCAATGTCC-3' and 5'-GGCCCCATTTTGCATTTTTATTAG-3'  
*Atg8a* (CG32672):  
 5'-TCGCAAATATCCAGACCGTGTGCCCGTC-3' and 5'-GCCGATGTTGGTGAATGACGTTGTTAC-3'

### Image Analysis

For image analysis, single-channel confocal images were converted into grayscale and the number and area of protein aggregates was measured in an automated way with the “Analyze Particle” function of ImageJ on the basis of polyubiquitin immunoreactivity. A cut-off of 10 pixels was applied to exclude background staining from the analysis. A similar approach was used to count vesicles.

In immunoelectron microscopy images, the total number of gold particles was counted to estimate the presence of protein aggregates.

Quantification of the intensity of antibody staining was done by measuring the mean fluorescence intensity with the Histogram function of Photoshop (Adobe) in single confocal images taken with the same settings.

### Transmission and Immunogold-Electron Microscopy

For transmission electron microscopy (TEM), thoraces were dissected and incubated in fixative (2% formaldehyde, 2.5% glutaraldehyde and 0.06% picric acid in 100 mM cacodylate buffer, pH 7.2) and processed as previously described (Bai et al., 2007).

For immunogold-electron microscopy, thoraces were fixed for 40 min in 0.1% Triton X-100 and 4% paraformaldehyde in 0.1M Sodium Phosphate buffer pH 7.4 and embedded in LR White resin (Electron Microscopy Sciences). ~80 nm thick LR White sections were picked up on formvar/carbon coated copper grids for immunolabeling.

The gold-labeling was carried out at room temperature on a piece of parafilm. Anti-ubiquitin (1:50 P4D1, Cell Signaling) antibodies and protein A gold were diluted in PBS with 0.1% Triton X-100 and 1% BSA. The diluted antibody solution was centrifuged 1 min at 14000 rpm prior to labeling to avoid possible aggregates. Grids were floated on drops of PBS with 0.1% Triton X-100 and 1% BSA for 10 min to block for unspecific labeling, transferred to 5 $\mu$ l drops of primary antibody and incubated for 30 min. The grids were then washed in 4 drops of PBS for a total of 15 min, transferred to 5 $\mu$ l drops of Protein-A gold for 20 min, washed in 4 drops of PBS for 15 min and 6 drops of double distilled water. Grids were picked up with metal loops and the excess liquid was removed by streaking on a filter paper. Post-staining of the LR White sections was done with 0.3% lead citrate. The grids were examined in a TecnaiG<sup>2</sup> Spirit BioTWIN mission electron microscope and images were recorded with an AMT 2k CCD camera (courtesy of Maria Ericsson, Harvard Medical School EM Facility).

### Western Blot and Biochemical Analysis of Detergent-Insoluble Fractions

Biochemical Analysis of detergent-insoluble fractions was done as previously (Cumming et al., 2008; Nezis et al., 2008; Tofaris et al., 2003). In brief, either fly heads and abdomens, or thoraces were dissected from at least 15 male flies and homogenized in ice-cold PBS with 1% Triton X-100 containing protease and phosphatase inhibitors. Homogenates were centrifuged at 14000 rpm at 4°C and supernatant collected (Triton X-100 soluble fraction). The remaining pellet was washed in ice-cold PBS with 1% Triton X-100. The pellet was then resuspended in RIPA buffer containing 8M urea and 5% SDS, centrifuged at 14000 rpm at 4°C, and collected supernatants (Triton X-100 insoluble fraction) were analyzed on 4%–20% SDS-PAGE. Western blots were probed with anti-ubiquitin antibodies (P4D1, Cell Signaling; 1:1000) and either anti- $\alpha$ -Tubulin or anti-Histone H3 antibodies (Cell Signaling, 1:1000) as loading controls.


For densitometry of western blots, band intensity was quantified with the Histogram function of Photoshop.

### SUPPLEMENTAL REFERENCES

Bai, J., Hartwig, J. H., and Perrimon, N. (2007). SALS, a WH2-domain-containing protein, promotes sarcomeric actin filament elongation from pointed ends during *Drosophila* muscle growth. *Dev. Cell* 13, 828-842.

Clyne, P. J., Brotman, J. S., Sweeney, S. T., and Davis, G. (2003). Green fluorescent protein tagging *Drosophila* proteins at their native genomic loci with small P elements. *Genetics* 165, 1433-1441.

- Cumming, R. C., Simonsen, A., and Finley, K. D. (2008). Quantitative analysis of autophagic activity in *Drosophila* neural tissues by measuring the turnover rates of pathway substrates. *Methods Enzymol.* 451, 639-651.
- Curran, S. P., Wu, X., Riedel, C. G., and Ruvkun, G. (2009). A soma-to-germline transformation in long-lived *Caenorhabditis elegans* mutants. *Nature* 459, 1079-1084.
- Hess, N. K., Singer, P. A., Trinh, K., Nikkhoy, M., and Bernstein, S. I. (2007). Transcriptional regulation of the *Drosophila melanogaster* muscle myosin heavy-chain gene. *Gene Expr. Patterns* 7, 413-422.
- Huang, H., Potter, C. J., Tao, W., Li, D. M., Brogiolo, W., Hafen, E., Sun, H., and Xu, T. (1999). PTEN affects cell size, cell proliferation and apoptosis during *Drosophila* eye development. *Development* 126, 5365-5372.
- Miron, M., Verdu, J., Lachance, P. E., Birnbaum, M. J., Lasko, P. F., and Sonenberg, N. (2001). The translational inhibitor 4E-BP is an effector of PI(3)K/Akt signaling and cell growth in *Drosophila*. *Nat. Cell Biol.* 3, 596-601.
- Puig, O., Marr, M. T., Ruhf, M. L., and Tjian, R. (2003). Control of cell number by *Drosophila* FOXO: downstream and feedback regulation of the insulin receptor pathway. *Genes Dev.* 17, 2006-2020.
- Pulipparacharuvil, S., Akbar, M. A., Ray, S., Sevrioukov, E. A., Haberman, A. S., Rohrer, J., and Kramer, H. (2005). *Drosophila* Vps16A is required for trafficking to lysosomes and biogenesis of pigment granules. *J. Cell Sci.* 118, 3663-3673.
- Ranganayakulu, G., Schulz, R. A., and Olson, E. N. (1996). Wingless signaling induces nautilus expression in the ventral mesoderm of the *Drosophila* embryo. *Dev. Biol.* 176, 143-148.
- Schuster, C. M., Davis, G. W., Fetter, R. D., and Goodman, C. S. (1996). Genetic dissection of structural and functional components of synaptic plasticity. I. Fasciclin II controls synaptic stabilization and growth. *Neuron* 17, 641-654.
- Teleman, A.A., Hietakangas, V., Sayadian, A. C., and Cohen, S. M. (2008). Nutritional control of protein biosynthetic capacity by insulin via Myc in *Drosophila*. *Cell Metab.* 7, 21-32.
- Tofaris, G. K., Razaq, A., Ghetti, B., Lilley, K. S., and Spillantini, M. G. (2003). Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. *J. Biol. Chem.* 278, 44405-44411.
- Zheng, X., Yang, Z., Yue, Z., Alvarez, J. D., and Sehgal, A. (2007). FOXO and insulin signaling regulate sensitivity of the circadian clock to oxidative stress. *Proc. Natl. Acad. Sci. USA* 104, 15899-15904.




**Figure S1. Mhc-Gal4 Drives Transgene Expression Specifically in Muscles, Related to Figure 1 and Figure 6**

(A–D) Overview of flies overexpressing *EGFP* with the Mhc-Gal4 driver (*UAS-srcEGFP/+ Mhc-Gal4/+*; magnification is 10x). GFP fluorescence (green) is detected to identify the tissues where Mhc-Gal4 can drive transgene expression. (A and D) Strong GFP fluorescence is detected in muscles of the thorax (direct and indirect flight muscles) and in leg muscles. Weaker GFP fluorescence is detected in head and abdominal muscles (not shown).


(E–G) In *UAS-srcEGFP/+ Mhc-Gal4/+* flies, no EGFP fluorescence is detected in the adipose tissue (E, peripheral fat body of the abdomen), the eye (F), and the brain (G). Similar results were obtained by driving the expression of other transgenes encoding GFP-tagged proteins (not shown).

(H–K) Transgene expression is maintained with age specifically in muscles, as assessed by monitoring GFP expression at 5 (H–I) and 8 weeks (J–K) of age. No GFP expression was detected in nonmuscle tissues (H–K).

Altogether, these observations indicate that Mhc-Gal4 drives transgene expression specifically in skeletal muscles but not in other tissues, including the adipose tissue, retina, and brain. This observation is consistent with previous studies reporting that *Mhc* is specifically expressed in muscles and that Mhc-Gal4 is a muscle specific Gal4 driver (Demontis and Perrimon, 2009; Hess et al., 2007; Schuster et al., 1996).



**Figure S2. Mhc-Gal4 Drives *foxo* Overexpression in Muscles without Affecting Developmental Growth and Differentiation, Related to Figure 1**  
 (A–D) Staining of indirect flight muscles with phalloidin (F-actin) and anti-Tropomyosin antibodies, and Mhc-GFP (WeeP26) fluorescence. The distribution of the sarcomeric components F-actin, Tropomyosin, and Mhc is similar in *Mhc-Gal4/Mhc-GFP* and *UAS-foxo/+ Mhc-Gal4/Mhc-GFP* flies, indicating that muscle differentiation and sarcomere assembly are unaltered. Scale bar, 20  $\mu$ m. (C–D) Higher magnification panels display Mhc-GFP fluorescence of *Mhc-Gal4/Mhc-GFP* and *UAS-foxo/+ Mhc-Gal4/Mhc-GFP* flies.  
 (E) *foxo* overexpression does not substantially affect developmental growth, as estimated by measuring the variation (%) in average body weight of 1-week-old flies (n[flies per batch] = 25, n[batch] = 2; standard deviation is indicated).




**Figure S3. Overexpression in Adulthood of Wild-Type and Constitutive Active *foxo* Preserves Muscle Proteostasis, Related to Figure 1 and Figure 2**

(A–H) Staining of indirect flight muscles with overexpression of either wild-type or constitutive active (*ca*) *foxo*. Transgene expression is temporally controlled with the temperature sensitive tubulin-Gal80<sup>ts</sup> to achieve adult onset transgene expression with the muscle Dmef2-Gal4 driver at 29°C. Overexpression of both wild-type (B and F) and constitutive active *foxo* (C and G) results in preservation of proteostasis, as exemplified by decreased deposition of protein aggregates (Polyubiquitin and Ref(2)P immunoreactivities) at 5 weeks of age, in comparison with controls (the Dmef2-Gal4 driver [A and E], and the UAS-*foxo* transgene alone) (D and H)). Scale bar is 20 μm.

(I) Fold change in the cumulative area of protein aggregates at 1 (yellow) and 5 (green) weeks of age from muscles of different animals indicates significant preservation of proteostasis in response to overexpression of wild-type or constitutive active *foxo* (\**p* < 0.05; SEM is indicated with *n*).

(J) Dmef2-Gal4 drives transgene expression specifically in all muscles (including thoracic and abdominal muscles) at both 1 and 5 weeks of age.



**Figure S4. FOXO Induces the Expression of *Hsp70* and Associated Folding Cochaperones, Related to Figure 2**

(A) *Hsp70* is a key player in proteostasis via its association with co-chaperones (*Hsp40* and *Hsp90*) and co-factors involved in protein folding (*Hip* and *Hop*) and degradation (*CHIP* and *Chap*). The mRNA levels of *Hsp70* increase in thoracic muscles at 1 week of age in response to *foxo* overexpression (red; *UAS-foxo/+*; *Mhc-Gal4/+*) in comparison with controls (blue; *Mhc-Gal4/+*). A significant increase is also detected in the mRNA levels of the co-chaperones *Hsp40* and *Hsp90* and co-factors involved in protein folding (*Hop*) but not in protein degradation (*Chip*, *Chap*) and *Hsc70*. Error bars represent SEM with  $n = 4$  and  $*p < 0.05$ ;  $**p < 0.01$ . Regulated genes have several putative FOXO binding sites (numbers in box) in their proximal (1 kb) promoter region (green: Fork-head Responsive Element (FRE); yellow: Insulin Responsive Element (IRE)).

(B) Luciferase assays in cell culture using wild-type (wt) and mutant versions ( $\Delta$ FRE) of the promoter regions of FOXO-regulated chaperones. Green and yellow


---

boxes indicate FREs and IREs in wild-type (wt) reporters, respectively, while a red star denotes mutation of a FOXO binding site in the mutant version of the promoter (arrow denotes ATG). (B) Relative Luciferase activity of wt and  $\Delta$ FRE mutant reporters, normalized to an *actin5c* promoter-based Luciferase reporter. *Foxo* overexpression increases the transcriptional activity of the wt Luciferase reporters, which is suppressed by the removal of FOXO binding sites ( $\Delta$ FRE mutant reporters). Error bars represent sem with  $n = 4$  and \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ . [Table S2](#) provides information on the promoter regions used for the construction of Luciferase reporters.

(C) Western blot analysis of Triton X-100 insoluble fractions from thoraces of syngenic flies with or without *Hsp70* overexpression in muscles. Thoraces from young flies (1 week old, black) are compared with thoraces from old flies (6 weeks old, red). Note a similar deposition of Ubiquitin-conjugated proteins in old flies independent of *Hsp70* overexpression. Quantification of ubiquitin-conjugated proteins levels normalized to Tubulin levels is indicated (normalized value).

(D) Immunostaining of indirect flight muscles from wild-type old flies (5 weeks of age) with an anti-Hsp70 antibody. Hsp70 immunoreactivity (green) is detected in the cytoplasm of young flies (not shown) and old flies, where it is additionally detected in polyubiquitin protein aggregates (red). Association of Hsp70 with protein aggregates may possibly decrease their toxicity (proteotoxicity). F-actin (blue, phalloidin staining) identifies myofibrils. Scale bar is 20  $\mu$ m.






**Figure S5. Minor Contribution of *Hsp70* Overexpression in Muscles to the Systemic Regulation of Aging, Related to Figure 4 and Figure 6**

(A) *Hsp70* overexpression has a partial effect on muscle function (not shown) and life span in comparison with syngenic control flies. Median and maximum life span: *Mhc-Gal4/+* = 56 and 80 days ( $n = 774$ ); *Mhc-Gal4/UAS-Hsp70* = 62 and 84 days ( $n = 626$ );  $p < 0.01$ ). Relative *Hsp70* mRNA levels are detected in thoraces from control (blue) and *Hsp70* overexpressing (red and green) flies by qPCR (sem is indicated with  $n = 4$ ; \* $p < 0.05$  and \*\* $p < 0.01$ ).


(B and C) Accumulation of polyubiquitinated proteins in nonmuscle tissues of flies overexpressing *Hsp70* in Muscles. (B) Western blot of Triton X-100 insoluble fractions from abdominal and head tissues of syngenic flies with or without *Hsp70* overexpression in muscles (*Mhc-Gal4/+*; and *Mhc-Gal4/UAS-Hsp70*) at 1 (young) and 6 weeks (old) of age. Note a similar accumulation of Ubiquitin-conjugated proteins with age, indicating that *Hsp70* overexpression in muscles is not sufficient per se to mitigate the loss of proteostasis in non-muscle tissues. Normalized values (based on  $\alpha$ -Tubulin levels) are shown.

(C) Immunostaining of adipose tissue (peripheral fat body of the abdomen) from flies with or without *Hsp70* overexpression in muscles at 6 weeks of age. *Hsp70* immunoreactivity (green) is detected in the cytoplasm and associated with some polyubiquitin protein aggregates (red) that accumulate in both conditions. F-actin staining is shown in blue. Scale bar, 20  $\mu\text{m}$ .



**Figure S6. Prominence of Muscle Aging Is Seemingly Not Affected by *foxo* Overexpression in the Abdominal Fat Body, Related to Figure 6** (A) Age-related changes in the cumulative area of protein aggregates are more prominent in muscles in comparison with other tissues (data displayed are from Figure 1 and Figure 6).

(B) Western blot analysis of Triton X-100 insoluble fractions from 5 weeks old S106GS-Gal4 flies at 29°C, with or without the UAS-foxo transgene, and either ethanol (EtOH, mock) or the inducer of expression mifepristone (S106GS-Gal4 is dependent on this progesterone analog to drive UAS-construct expression in the fat body (Giannakou et al., 2004; Hwangbo et al., 2004)). FOXO activation in the fat body may regulate systemic proteostasis, although no substantial difference in the deposition of protein aggregates in muscles (thoraces) is observed in the various conditions tested.



**Figure S7. Expression of Mutant Human Huntington's Disease Proteins in Muscles Is Sufficient to Decrease Life Span, Related to Figure 4 and Figure 7**

(A and B) GFP-positive protein aggregates are detected in muscles from both young (2 days old) and older flies (21 days old) upon overexpression in muscles of GFP-tagged, aggregation-prone human Huntington's disease proteins. Note that Huntington's disease protein aggregates are distinct from aggregates of endogenous damaged proteins (identified via polyubiquitin immunoreactivity, red) in both confocal and transmission electron microscopy (inset in B). Scale bars, 20  $\mu$ m (A, confocal microscopy) and 500 nm (inset in B, electron microscopy).

(C) Overexpression of Huntington's disease proteins in muscles is sufficient to decrease life span, indicating that muscle proteostasis is limiting for life expectancy ( $p < 0.001$ , with  $n[Mhc-Gal4/+]$  = 1264,  $n[UAS-HD-Q72-GFP/+; +/+; Mhc-Gal4/+]$  = 372, and  $[UAS-HD-Q103-GFP/+; +/+; Mhc-Gal4/+]$  = 490).